Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877470 | 0.84 | ERN1 (0.48) | ERN1PTGS1PTGS2ALOX5ALDH1A1 | |
| SCHEMBL5757508 | 0.82 | ERN1 (0.55) | ERN1 | |
| SCHEMBL16229132 | 0.80 | ERN1 (0.48) | ERN1CYP3A4ALDH1A1TSHR | |
| SCHEMBL22128474 | 0.80 | ALDH1A1 (0.35) | ERN1CYP3A4ALDH1A1TSHR | |
| SCHEMBL20607061 | 0.79 | ERN1 (0.44) | ERN1PTGS1PTGS2CYP3A4MAPT | |
| SCHEMBL9821011 | 0.77 | ALDH1A1 (0.33) | ERN1CYP3A4ALDH1A1TSHR | |
| SCHEMBL27468625 | 0.77 | ERN1 (0.47) | ERN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL31088864 | 0.75 | CA1 (0.39) | PTGS1PTGS2MAPTALOX5ALDH1A1 | |
| SCHEMBL12885938 | 0.75 | CA1 (0.39) | PTGS1PTGS2CYP3A4MAPTALOX5 | |
| SCHEMBL2925324 | 0.74 | ERN1 (0.52) | ERN1CYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-108779076-B | 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives | 大塚制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| EP-3423440-B9 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3423440-B1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3423440-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ERN1 3152/4885PTGS1 1074/4885PTGS2 982/4885 |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ERN1 3152/4885PTGS1 1074/4885PTGS2 982/4885 |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ERN1 3152/4885PTGS1 1074/4885PTGS2 982/4885 |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | ERN1 3152/4885PTGS1 1074/4885PTGS2 982/4885 |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | VHL, H1-5, PRMT5 | ERN1 3152/4885PTGS1 1074/4885PTGS2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.